Definition

A preparation of T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) six transmembrane epithelial antigen of the prostate 1 (STEAP1), with potential immunostimulating and antineoplastic activities. Upon administration, anti-STEAP1 CAR T cells recognize and bind to STEAP1-expressing tumor cells, thereby inducing selective toxicity in STEAP1-expressing tumor cells. STEAP1 is overexpressed in a variety of cancer cell types.